SRR5903555
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.520
- HEDGEHOG_SIGNALING+0.440
- TGF_BETA_SIGNALING+0.410
- WNT_BETA_CATENIN_SIGNALING+0.380
- APICAL_JUNCTION+0.340
- NOTCH_SIGNALING+0.340
- GLYCOLYSIS+0.270
- HYPOXIA+0.250
- PANCREAS_BETA_CELLS+0.250
Top 10 suppressed
- PEROXISOME-0.350
- CHOLESTEROL_HOMEOSTASIS-0.300
- ADIPOGENESIS-0.290
- BILE_ACID_METABOLISM-0.280
- INTERFERON_ALPHA_RESPONSE-0.280
- OXIDATIVE_PHOSPHORYLATION-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- FATTY_ACID_METABOLISM-0.220
- INTERFERON_GAMMA_RESPONSE-0.190
- ALLOGRAFT_REJECTION-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_6109_T1A_RNA | — | C | 0.818 |
| 2 | TCGA-CN-6022-01A-21R-1686-07 | — | — | 0.798 |
| 3 | TCGA-60-2708-01A-01R-0851-07 | — | cohortSQ1 | 0.792 |
| 4 | SRR9879274 | — | cohortSQ1 | 0.782 |
| 5 | SRR8943032 | — | — | 0.781 |
| 6 | ERR2208919 | — | — | 0.775 |
| 7 | TCGA-CV-6950-01A-11R-1915-07 | — | — | 0.774 |
| 8 | b71da73b-05c2-49e1-85b8-d93980ffe15d | — | — | 0.771 |
| 9 | SRR8518161 | — | E | 0.765 |
| 10 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.440 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |